Research Summary

My research program has been highly focused on identifying and overriding molecular mechanisms of resistance to targeted therapeutics in hematopoietic malignancies, and is highly translational in nature. I therefore rely heavily upon HDFCCC infrastructure, including the Phase I Unit in the Developmental Therapeutics Program, the Tissue Core, the Bioinformatics Core, and the Mouse Therapeutics Core Facility. Additionally, I have ongoing Intra- and Inter-Programmatic collaborations with numerous Members and Associate Members, including Benjamin Braun, Emmanuelle Passegue, Scott Kogan, Mignon Loh, and Kevan Shokat.

Research Funding

  • August 1, 2015 - July 31, 2019 - Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML, Principal Investigator. Sponsor: NIH, Sponsor Award ID: R01CA194094
  • April 8, 2013 - March 31, 2018 - Crenolanib and ponatinib for the treatment of FLT3 mutant AML, Principal Investigator. Sponsor: NIH, Sponsor Award ID: R01CA176091
  • April 17, 2012 - March 31, 2017 - Mechanisms of resistance to clinically-effective FLT3 kinase inhibitors in AML, Principal Investigator. Sponsor: NIH, Sponsor Award ID: R01CA166616
  • September 23, 2015 - August 31, 2016 - Pre-IND study of PMT-254, a pan-FLT3 inhibitor for the treatment of FLT3 driven cancers., Principal Investigator. Sponsor: NIH, Sponsor Award ID: R41CA199753

Education

University of California, Berkeley, BS,1984, Genetics
University of California, Los Angeles, PhD, 1992, Microbiology & Molecular Genetics
University of California, Los Angeles, MD, 1996, Medicine

Honors & Awards

  • 1989-1991
    National Institutes of Health Predoctoral Award in Tumor Cell Biology
  • 1995
    Alpha Omega Alpha Medical Student Research Prize
  • 1995-2003
    UCLA Specialty Training and Advanced Research (STAR) Award
  • 2001-2004
    Leukemia and Lymphoma Society Career Development Award for Fellows
  • 2003-2005
    NIH K12 Award in Clinical Pharmacology
  • 2004-2007
    Leukemia and Lymphoma Society Career Development Award for Special Fellows
  • 2006-2009
    Doris Duke Charitable Foundation Clinical Scientist Development Award
  • 2009-2014
    Leukemia and Lymphoma Society Scholar in Clinical Research Award

Selected Publications

  1. Gul A, Stewart TF, Mantia CM, Shah NJ, Gatof ES, Long Y, Allman KD, Ornstein MC, Hammers HJ, McDermott DF, Atkins MB, Hurwitz M, Rini BI Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.  View on PubMed
  2. Shah NJ, Al-Shbool G, Blackburn M, Cook M, Belouali A, Liu SV, Madhavan S, He AR, Atkins MB, Gibney GT, Kim C Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.  View on PubMed
  3. Hutchison IL, Ridout F, Cheung SMY, Shah N, Hardee P, Surwald C, Thiruchelvam J, Cheng L, Mellor TK, Brennan PA, Baldwin AJ, Shaw RJ, Halfpenny W, Danford M, Whitley S, Smith G, Bailey MW, Woodwards B, Patel M, McManners J, Chan CH, Burns A, Praveen P, Camilleri AC, Avery C, Putnam G, Jones K, Webster K, Smith WP, Edge C, McVicar I, Grew N, Hislop S, Kalavrezos N, Martin IC, Hackshaw A Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort.  View on PubMed
  4. Shah NJ, Kelly WJ, Liu SV, Choquette K, Spira A Product review on the Anti-PD-L1 antibody atezolizumab.  View on PubMed
  5. Pannu J, Poole S, Shah N, Shah NH Assessing Screening Guidelines for Cardiovascular Disease Risk Factors using Routinely Collected Data.  View on PubMed
  6. Saglio G, le Coutre P, Cortes J, Mayer J, Rowlings P, Mahon FX, Kroog G, Gooden K, Subar M, Shah NP Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.  View on PubMed
  7. Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom RT, Hobbs G, Jagasia M, Kantarjian HM, Kropf P, Metheny L, Moore JO, Ontiveros E, Purev E, Quiery A, Reddy VV, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Tibes R, Yang DT, Gregory K, Sundar H, Deininger M, Radich JP NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.  View on PubMed
  8. Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Hochhaus A, Saglio G Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.  View on PubMed
  9. Wauters L, Brown T, Venter C, Dziubak R, Meyer R, Brogan B, Walsh J, Fox AT, Shah N Cow's Milk Allergy Prescribing Is Influenced by Regional and National Guidance.  View on PubMed
  10. Apsel Winger B, Shah NP PPAR?: Welcoming the New Kid on the CML Stem Cell Block.  View on PubMed
  11. Kesarwani M, Huber E, Kincaid Z, Evelyn CR, Biesiada J, Rance M, Thapa MB, Shah NP, Meller J, Zheng Y, Azam M Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.  View on PubMed
  12. Smith CC, Zhang C, Lin KC, Lasater EA, Zhang Y, Massi E, Damon LE, Pendleton M, Bashir A, Sebra R, Perl A, Kasarskis A, Shellooe R, Tsang G, Carias H, Powell B, Burton EA, Matusow B, Zhang J, Spevak W, Ibrahim PN, Le MH, Hsu HH, Habets G, West BL, Bollag G, Shah NP Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.  View on PubMed
  13. Chatterjee A, Ghosh J, Ramdas B, Mali RS, Martin H, Kobayashi M, Vemula S, Canela VH, Waskow ER, Visconte V, Tiu RV, Smith CC, Shah N, Bunting KD, Boswell HS, Liu Y, Chan RJ, Kapur R Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.  View on PubMed
  14. Tajon CA, Seo D, Asmussen J, Shah N, Jun YW, Craik CS Sensitive and selective plasmon ruler nanosensors for monitoring the apoptotic drug response in leukemia.  View on PubMed
  15. Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.  View on PubMed
  16. Shah N, Rutherford C, Matevosyan K, Shen YM, Sarode R Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).  View on PubMed
  17. Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.  View on PubMed
  18. Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Müller MC, Lambert A, Matloub Y, Hochhaus A Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or int  View on PubMed
  19. Paquette RL, Nicoll J, Chalukya M, Gondek L, Jasek M, Sawyers CL, Shah NP, Maciejewski J Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib.  View on PubMed
  20. Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).  View on PubMed

Go to UCSF Profiles, powered by CTSI